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The physiological function of epithelia is transport of ions, nutrients, and fluid either in
secretory or absorptive direction. All of these processes are closely related to cell volume
changes, which are thus an integrated part of epithelial function. Transepithelial transport
and cell volume regulation both rely on the spatially and temporally coordinated function
of ion channels and transporters. In healthy epithelia, specific ion channels/transporters
localize to the luminal and basolateral membranes, contributing to functional epithelial
polarity. In pathophysiological processes such as cancer, transepithelial and cell volume
regulatory ion transport are dys-regulated. Furthermore, epithelial architecture and
coordinated ion transport function are lost, cell survival/death balance is altered, and
new interactions with the stroma arise, all contributing to drug resistance. Since altered
expression of ion transporters and channels is now recognized as one of the hallmarks
of cancer, it is timely to consider this especially for epithelia. Epithelial cells are highly
proliferative and epithelial cancers, carcinomas, account for about 90% of all cancers. In
this review we will focus on ion transporters and channels with key physiological functions
in epithelia and known roles in the development of cancer in these tissues. Their roles
in cell survival, cell cycle progression, and development of drug resistance in epithelial
cancers will be discussed.
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cancer, stroma, secretion
INTRODUCTION
Broadly speaking, epithelia are organized into sheets, tubes,
or glandular structures, and perform complex tasks of trans-
porting ions, organic molecules, and water for which specific
ion channels/transporters are required. The majority of cancers
are of epithelial origin, and the altered ion channel/transporter
expression, which is emerging as one of the hallmarks of can-
cer in general (Prevarskaya et al., 2010; Lehen’kyi et al., 2011),
is also a marked characteristic of epithelial cancers. In this
review we will first outline the ion transport mechanisms oper-
ating in epithelia under physiological conditions of ion/fluid
transport and cell volume regulation. Next, we will review and
Abbreviations: ABC, ATP-binding cassette; AVD, apoptotic volume decrease; α-
SMA, α-smooth muscle actin; BK, big conductance K+ channel, also named
KCa1.1 and maxi-K+ ; CA, carbonic anhydrase; CAFs, cancer associated fibrob-
lasts; [Ca2+]I , intracellular Ca2+ activity; CFTR, the cystic fibrosis transmembrane
conductace regulator; EATC’s, Ehrlich ascites tumour cells; ECM, extracellular
matrix; EGF, epidermal growth factor; ELA, Ehrlich Lettre ascites carcinoma;
EMT, epithelial-to-mesenchymal transition; ERK1/2, extracellular signal regulated
kinase; HICCS, hypertonicity-induced cation channels; HIF1α, hypoxia-inducible
factor-1α; IK, intermediate conductance K+ channel, also named KCa3.1; MAPK,
mitogen-activated protein kinase; MCT, monocarboxylate transporters; MDR,
multi drug resistance; NBC, Na+-HCO−3 transporter; NHE, Na+/H+ exchanger;
NKCC1, Na+-K+-2Cl− cotransporter; VRAC, volume regulated Cl− channel;
OSR1, oxidative stress responsive kinase; pHi, intracellular pH; pHe, extracellular
pH; PCD, programmed cell death; PSCs, pancreatic stellate cells; PDAC, pancreatic
ductal adenocarcinoma; RVI, regulatory volume increase; RTK, receptor tyrosine
kinase; RVD, regulatory volume decrease; SOCE, store-operated calcium entry;
SPAK, SPS-related proline/alanine-rich kinase; TME, tumor microenvironment;
VDAC-1, mitochondrial voltage-dependent anion channel; TRP, transient recep-
tor potential channels; VEGF, vascular endothelial growth factor; WNK, with no
lysine kinase; ZO-1, tight junction protein.
critically discuss how dys-regulation of cell volume or given
ion transporters can lead to loss of epithelial architecture,
altered cell survival, tumor progression, and drug resistance.
The focus will be on cancers of secretory epithelia, primar-
ily pancreatic ductal adenocarcinoma (PDAC) and mammary
cancer.
PHYSIOLOGY OF EPITHELIAL TRANSPORT AND ROLE OF
CELL VOLUME
Animal cells are subjected to transmembrane osmotic gradients
in a number of physiologically relevant conditions, including:
(i) ion/nutrient transport followed by osmotically obliged water
movement; (ii) metabolic activity generating or requiring osmot-
ically active substances; or (iii) altered extracellular osmolarity
of the environment [see Hoffmann et al. (2009)]. Epithelial cells
are of special interest because they carry out net transport of
electrolytes, nutrients, and water in the secretory or reabsorptive
direction, conditions in which cell volume regulation is a par-
ticular challenge. A question that has raised substantial interest
in the field is how well cell volume regulation is achieved under
these conditions, and to what extent cell volume changes con-
tribute to the regulation of secretion/absorption. Furthermore,
little is known about what happens to cell volume regulation
if the normal vectorial epithelial transport is prevented or dys-
regulated. It is well documented that several pathophysiological
conditions, including altered Na+/K+ balance and acid/base dis-
turbances caused by renal disease, or cardiac or brain ischemia,
are associated with dys-regulation of cell volume regulatory
transporters, and that the associated cell volume disturbance
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contributes importantly to the pathology of these conditions (for
reviews, see Lang, 2007; Hoffmann et al., 2009; Pedersen et al.,
2011).
In absorptive epithelia such as the renal tubules, small intes-
tine, gallbladder, and skin, the most common mechanism of
transepithelial transport involves luminal channels and trans-
porters that utilize the plasma membrane Na+ gradient for salt
and nutrient transport, which would tend to swell the cells.
Isosmotic transport and recovery of cell volume under these
conditions is likely achieved through activation of basolateral
stretch-activated K+ channels, volume regulated Cl− channels
(VRAC), and increased activity of the Na+/K+ pump, followed
by exit of ions/nutrients and osmotically obliged water across the
basolateral membrane (Lang et al., 1998; Vanoye and Reuss, 1999;
Schultz and Dubinsky, 2001; Hoffmann et al., 2009; Bachmann
et al., 2011).
Here, we will focus on secretory epithelia such as pancreas,
salivary glands, colorectum, stomach, mammary glands, and
prostate, which, as will be discussed below, might not fully reg-
ulate their cell volume during stimulated secretion. Notably,
several of these epithelia are among the tissues in the body
that are most commonly afflicted by cancer (Siegel et al.,
2013). One of the most common mechanisms for initiating
fluid secretion by agonists or hormones is opening of lumi-
nal Cl− channels and luminal and basolateral K+ channels,
and this also leads to a cell volume decrease. A number of
transport mechanisms on the basolateral membrane are acti-
vated to provide ions for luminal exit and thus secretion, and
this will potentially lead to regain of cell volume. Concurrently,
the cells need to regulate their intracellular pH (pHi), and for
cells exhibiting net secretion of H+ or HCO−3 (stomach, pan-
creatic ducts), this is a particular challenge. Figure 1A shows
the basic model for ion transport across secretory cells such
as pancreatic duct cell. As seen, this model includes a toolbox
of ion channels and transporters (Novak et al., 2011; Frizzell
and Hanrahan, 2012; Wilschanski and Novak, 2013), some of
which are dys-regulated in cancer, as will be described below.
The ion channels include: the cystic fibrosis transmembrane
conductace regulator (CFTR) and Ca2+-activated Cl− channels
(ANO1/TMEM16A), intermediate and large conductance K+
channels (IK—KCa3.1; BK—KCa1.1), volume sensitive KCNQ1
channels, and possibly voltage-regulated channels (HERG—
Kv11.1; EAG2—Kv10.2) (Hayashi et al., 2012; Wang et al., 2013).
The ion transporters include Na+-K+-2Cl− cotransporters
(NKCC1), Na+/H+ exchangers (NHEs), Cl−/HCO−3 exchang-
ers (SLC26A3,6 and SCL4A family), Na+-HCO−3 transporters
(NBCs) and H+/K+-pumps. Another mechanism of achieving
secretion, which is beyond the scope of this review, is that driven
at least in part by exocytosis, such as in mammary epithelial cells
secreting milk, or, for example, parietal cell secreting hydrochlo-
ric acid following exocytotic recruitment of the H+/K+ pump
from tubulovesicles to the apical membrane (Forte and Zhu,
2010).
In terms of cell volume, the crucial question is how ion/fluid
transport on the two opposing membranes is coordinated. The
main driving force for all these secondary- or tertiary- active
processes is provided by the Na+/K+-ATPase. For secretory
FIGURE 1 | The development of epithelial cancer and roles of ion
transport and cell volume. (A) Normal secreting epithelium showing net
movements of ions and fluid across the basolateral and luminal membranes.
Black arrows show the movement of ions and fluid across cell membranes.
The insert shows the detailed model of a cell with basic ion channels and
transporters that operate, for example, in pancreatic ducts, but are also
applicable to other secreting epithelia. The luminal Cl− channels include
CFTR and TMEM16A/ANO1, as well as a SLC26 family Cl−/HCO−3
exchanger. The basolateral membrane contains the Na+/K+/2Cl−
transporter NKCC1, SLC7 family Na+-HCO−3 cotransporters (NBCs), and the
Na+/H+ exchanger NHE1. The epithelium also expresses H+/K+ pumps, as
well as several types of K+ channels such as IK-KCa3.1, BK-KCa1.1, KCNQ1
and voltage-activated K+ channels, some of which may be expressed on
both luminal and basolateral membranes. The major Ca2+ and cAMP
signalling pathways are not elaborated and for simplicity, Ca2+
-channels/transporters and aquaporins are not included. (B) Carcinogenesis
and postulated dysregulation of cells volume and secretion. Increased
activity of fibroblastic cells, such as cancer associated fibroblasts (CAFs) and
pancreatic stellate cells (PSCs) (green). (C) The epithelial-to-mesenchymal
(EMT) transition showing cells that loose apico-basal polarity and the
appearance of some ion transporters from the lumimal membrane in the
rear of the cells and some from the basolateral membrane in the leading
edge, contributing to driving cell migration. (D) Progression to cancer,
showing tumor with extensive fibrosis (gray), fibrogenic cells (green) and
immune cells (blue). (Blood vessels are not shown). In the center of the
tumor cells may die, while surrounding cells are proliferating and cell volume
and corresponding ion transport is up-regulated (see the text).
epithelia, the classical view is that basolateral transporters are acti-
vated secondarily to ion movements across the apical membrane
due to alterations in electrochemical gradients or cell volume
changes. Regarding the cell volume, known shrinkage-activated
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proteins are NHE1, NKCC1, and some Transient receptor poten-
tial vanniloid (TRPV) channels; and swelling activated proteins
are volume regulated anion channels (VRAC), KCNQ1, two-
pore K+ channels and Ca2+-activated K+ channels (Hoffmann
et al., 2009). In addition to these transporters and channels,
other plasma membrane transporters are regulated by volume-
sensitive signaling pathways, including intracellular messengers,
phosphorylation, and complex interactions involving cytoskele-
tal reorganization, Ca2+-signaling, and signaling via integrins
and receptor tyrosine kinases (RTKs). For overview of these top-
ics the reader is referred to the recent review (Pedersen et al.,
2011). Here we just point out that recently discovered cell signal-
ing pathways involving volume- and low Cl−-sensitive With No
Lysine kinases (WNK), acting via Ste20-like kinases, SPS-related
proline/alanine-rich kinase (SPAK) and oxidative stress respon-
sive kinase (OSR1), may be key factors in secretory epithelia
as they regulate NKCC1 and other transporters (Kahle et al.,
2006; Hoffmann et al., 2009; McCormick and Ellison, 2011; Park
et al., 2012). Similarly, autocrine and paracrine signaling via
volume-sensitive ATP release and purinergic receptors may be
important regulators of key short- and long-term cell volume and
ion transport in epithelia and tumor models (Hug et al., 1994;
Pedersen et al., 1999; Sørensen and Novak, 2001; Koltsova et al.,
2011; see Novak, 2011). A number of ATP release mechanism
have been proposed, including ion channels and transporters,
and they utilize favorable electrochemical gradient (see Novak,
2011).
Nevertheless, in the acute/secretory state, the cell volume of
many native epithelial cells recovers only partially or does not
recover until the stimulus is withdrawn (Manabe et al., 2004;
Bachmann et al., 2007). For example, some secretory cells shrink
by more than 20% during stimulation and remain shrunken until
the stimulus is withdrawn (Dissing et al., 1990; Foskett, 1990;
Nakahari et al., 1990, 1991; Lee and Foskett, 2010) (Figure 1A).
The chronic events of altered volume regulation and/or ion
transporter expression might lead to pathological developments
associated with cancer.
LOSS OF EPITHELIAL POLARITY—IMPLICATIONS FOR ION
TRANSPORT
The polarized organization of ion transport proteins is essential
for the normal function of epithelia, and appears to involve the
interplay between the targeted delivery of transporters, restric-
tion by cell-cell junctions, and the fact that the transporters
reside in large protein-protein complexes linking them to the
actin- and spectrin-based cytoskeleton (Nelson, 2009). During
early stages of cancer development, the epithelial layer becomes
disorganized, loses its cell-cell adhesions, and undergoes a dra-
matic change from apical-basal polarity to a mesenchymal cell
type organization with a front-rear polarity (Figures 1B,C). This
process is known as epithelial-to-mesenchymal transition (EMT),
and has been well studied both for breast and pancreatic ade-
nocarcinomas (Foroni et al., 2012; Rhim et al., 2012). Although
the signaling mechanisms involved in EMT are far from fully
elucidated and are partially context- and cell-type dependent,
several central themes have been established. Upstream EMT fea-
tures include up-regulation of transcription factors such as Slug,
Snail, and Twist. Markers of the full-blown EMT include up-
regulation of α-smooth muscle actin (α-SMA), vimentin, and
fibronectin, and down-regulation of epithelial markers such as
E-cadherin, cytokeratins, and the tight junction protein ZO-1
(Kalluri and Weinberg, 2009; Nelson, 2009; De Craene and Berx,
2013). Notably, although a number of factors involved in polar-
ity switching are described (Nelson, 2009; Godde et al., 2010),
essentially nothing is known regarding the roles and regula-
tion of polarized transport proteins during EMT. Thus, it is an
open question how the tightly compartmentalized localization
of transport proteins gets “reinstructed” upon transition from
apical-basal to a front-rear polarity (Figure 1C). The net result,
however, is that at least some apical ion channels and transporters
relocalize to the rear end, while several that are basolaterally
located in epithelia move to the leading edge of the cell (compare
Figures 1A,C). This specific reorganization of ion channels and
transporters contributes importantly to cell migration (Schwab
et al., 2012). Given the known roles of many of these trans-
port proteins in cytoskeletal organization, signaling, and motility,
we speculate that contributions to EMT might be added to the
list of roles for dys-regulation of transport proteins in epithelial
cancers.
THE TUMORMICROENVIRONMENT (TME)
Tumors are highly complex tissues in which the cancer cells them-
selves are often the minority and co-exist with numerous other
cell types in a physical/chemical microenvironment which dif-
fers dramatically from that of the normal tissue (Figure 1D).
The tumor microenvironment (TME) undergoes extensive recip-
rocal interactions with the cancer cells and provides onco-
genic signals that exacerbate cancer progression. The detailed
properties of the TME have been excellently reviewed else-
where (Mueller and Fusenig, 2004; Kalluri and Zeisberg, 2006;
Pandol et al., 2009; Hanahan and Weinberg, 2011; Feig et al.,
2012; Hanahan and Coussens, 2012). In the following, we set
the stage for discussing the interrelationship of the TME with
dys-regulated ion transport, focusing on PDAC and mammary
adenocarcinoma.
THE CELLULAR COMPONENT OF THE TME
The predominant stromal cell type in many carcinomas, includ-
ing breast cancers, is cancer associated fibroblasts (CAFs) (Kalluri
and Zeisberg, 2006; Hanahan and Coussens, 2012). CAFs secrete
extracellular matrix (ECM) components and matrix-degrading
enzymes, and, being contractile, mechanically pull at the ECM,
increasing its stiffness (Kalluri and Zeisberg, 2006; Hanahan and
Coussens, 2012). CAFs also secrete numerous growth factors,
cytokines and vascular endothelial growth factor (VEGF), stim-
ulating tumor growth and, in general, angiogenesis (Kalluri and
Zeisberg, 2006; Hanahan and Coussens, 2012), though para-
doxically solid tumors show poor vascularization (see below).
In PDAC, pancreatic stellate cells (PSCs) play a role similar to
that of CAFs in breast cancer (Pandol et al., 2009; Feig et al.,
2012), although CAFs per se are also present in PDAC (Scarlett,
2013). Quiescent PSCs are present in low numbers in the normal
exocrine pancreas. PSCs become activated by exposure to factors
secreted by the cancer cells, rendering them myofibroblast-like,
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highly proliferative, and motile (Pandol et al., 2009; Feig et al.,
2012; Li et al., 2012). Excessive ECM deposition by PSCs is the
main source of the marked desmoplasia in PDAC (Figure 1D).
The PSCs also secrete growth factors, cytokines and chemokines,
stimulating immune cell infiltration, angiogenesis, and cancer cell
proliferation and motility (Pandol et al., 2009; Feig et al., 2012; Li
et al., 2012). Infiltrating immune cells are of major importance
in both mammary and pancreatic adenocarcinomas (Clark et al.,
2007). Recruited tumor-associated macrophages release growth
factors, chemokines, cytokines, and matrix-degrading enzymes,
stimulating angiogenesis, cancer cell growth and invasiveness
and further recruitment of pro-tumorigenic immune cells, while
blocking activation of anti-tumorigenic T cells (Kalluri and
Zeisberg, 2006; Pandol et al., 2009; Hanahan andWeinberg, 2011;
Kees and Egeblad, 2011). Other central cellular stromal compo-
nents are endothelial cells and pericytes (smooth-muscle-derived
cells surrounding the endothelium). Finally, cancer stem cells or
tumor-initiating cells have been found in the TME in both mam-
mary and pancreatic cancer (Hermann et al., 2007; Iqbal et al.,
2013).
CHEMICAL/PHYSICAL PROPERTIES OF THE TME
In addition to the wealth of cell types and secreted signal-
ing factors mentioned above that sets the TME apart from the
normal tissue, the TME also differs markedly from the nor-
mal tissue in its physical/chemical properties (see Harris, 2002;
Heldin et al., 2004; Vaupel, 2004; Egeblad et al., 2010; Provenzano
and Hingorani, 2013). Similar to the cellular component, the
physical/chemical microenvironment exhibits distinct spatial het-
erogeneity throughout the tumor and develops dynamically as
the cancer progresses. Because of the generally insufficient or col-
lapsed tumor vasculature in many solid tumors, many areas of
the TME are hypoxic or even anoxic (Harris, 2002). This has
been shown directly for breast cancer (Vaupel, 2004), whereas
evidence is more sparse for PDAC (see Feig et al., 2012). In
conjunction with cancer-associated metabolic changes and high
demand for energy and building blocks for anabolic reactions,
this results in glucose deprivation, elevated lactate levels, and
acidic extracellular pH (pHe) (Heldin et al., 2004; Vaupel, 2004).
Another consequence of the inefficient tumor vasculature and
lymph outflow is elevated interstitial fluid pressure. A third phys-
ical characteristic of mammary and especially pancreatic cancers
is that of desmoplasia—excessive accumulation and crosslinking
of fibrillar collagens. This stiffens the ECM, in turn favoring can-
cer progression through effects on cell motility, differentiation,
proliferation, and treatment response (Egeblad et al., 2010). In
PDAC tumors, which are highly fibrotic and hypovascular, it is
difficult for therapeutic agents to reach the tumor cells (Feig et al.,
2012; Provenzano andHingorani, 2013). Recent studies show that
enzymatic targeting of stroma, ablation of the physical barrier
improves vasculature and promotes drug delivery (Provenzano
et al., 2012).
It seems likely that, in addition to selecting for hypoxia resis-
tance and increased acid extrusion capacity (section Functional
interactions between the TME and ion transport dys-regulation),
the physically restricted TME with elevated interstitial pres-
sure will tend to select for increased cell volume regulatory
capacity due to the increased osmotic stress exposure. However,
to our knowledge, this has never been directly studied. In addi-
tion, one might expect that physical constraints, hypoxia and
necrosis will influence the concentration profiles of extracellular
nucleosides/-tides within the tumor, in turn affecting a spec-
trum of tumor resident cells via purinergic signalling (Di Virgilio,
2012) (Figure 1D).
FUNCTIONAL INTERACTIONS BETWEEN THE TME AND ION
TRANSPORT dys-REGULATION
While this has still been relatively little studied, it is clear that
dys-regulation of ion transport in cancer is involved in impor-
tant functional interactions with the TME. Firstly, the metabolic
switch induced (in part) by hypoxia increases acid production in
the cancer cells. This, in conjunction with hypoxia-induced ele-
vation of hypoxia-inducible factor-1α (HIF1α) levels increases
the expression and/or activity of acid-extruding ion transport
proteins and carbonic anhydrases (CAs). In breast cancer, these
include the Na+/H+ exchanger NHE1, the Na+-HCO−3 cotrans-
porter NBCn1, monocarboxylate transporters MCT1 andMCT4,
and CAIX (Bartosova et al., 2002; Lauritzen et al., 2010, 2012;
Pinheiro et al., 2010; Boedtkjer et al., 2013; see Cardone et al.,
2005) (Figure 2). In PDAC, evidence is much sparser, although
neurotensin-induced NHE1 activation in PDAC cell lines is
reported (Olszewski et al., 2010). Cytokines and growth factors
secreted by the cancer cells and stromal cells likely also con-
tribute to the up-regulation of ion transport. For instance, ErbB2
FIGURE 2 | Ion channels and transporters and cell volume changes
associated in normal and cancer cells. Cell sizes refer to expected cell
volume changes and lengths of arrows on cells indicates up- or
down-regulation or ion transporters/channels. Resistance to apoptosis is
associated with down-regulation of several channels and inhibition of some
channels (asterisks) induces resistance to apoptosis. In proliferation, several
transporters and channels are up-regulated and over-expressed in cancer
(see text). The right part of the figure shows ion transporters and channels
that would lead to cell volume increase and those in the lower part indicate
those that would lead to cell volume decrease. Large arrows next to named
ion channels/transporters indicate their up- or down-regulation in cancer.
Chronic activation of ion transport may lead to cell death. Dynamic
activation or suppression of ion transport/cell volume with specific signals,
in time or in given cells may lead to cancer development and progression.
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signaling increases NBCn1 expression and post-translationally
activates NHE1 by phosphorylation in its C-terminal cytoplasmic
domain (Lauritzen et al., 2010, 2012). In turn, ion transporters
play major roles in creating the TME. Increased acid extru-
sion from the cancer cells can cause extracellular pH (pHe) to
become as low as 6.0 in some tumor regions (Vaupel, 2004).
This favors further cancer development, e.g., through facilitating
ECM degradation and cell motility, resistance to chemother-
apy, and compromised anti-tumor function of cytotoxic T-cells
and natural killer cells (Ward et al., 2013), while their role
in maintaining pHi at or above the normal pH 7.0–7.4 favors
metabolic, migratory, and proliferative activity and counteracts
apoptotic death (Parks et al., 2011; Webb et al., 2011; Boedtkjer
et al., 2012). Finally, it has been suggested that NHE1 may
directly regulate ECM deposition by fibroblasts (Karydis et al.,
2009).
ROLES OF CELL VOLUME REGULATION IN CELL
PROLIFERATION AND PROGRAMMED CELL DEATH (PCD)
Importantly, cells do not have one preferred volume. Rather, the
volume set point depends on the functional state of the cell and
changes in cell volume serve as key physiological signals initiat-
ing downstream responses, such as transepithelial transport (see
above), proliferation, migration and cell death (Figure 2) (see
Hoffmann et al., 2009). Consequently, dysfunction of volume-
sensitive membrane transport proteins is associated with patho-
physiological conditions related to control of these processes,
including cancer.
CELL PROLIFERATION
Cell volume is a major factor in the regulation of cell cycle pro-
gression, with cell proliferation generally being inhibited by cell
shrinkage and stimulated by cell swelling, respectively (Anbari
and Schultz, 1993; Dubois and Rouzaire-Dubois, 2004; Rouzaire-
Dubois et al., 2005). Cell cycle progression depends on an increase
in cell volume, and the capacity for regulatory volume decrease
(RVD) changes during the cell cycle (see e.g., Hoffmann et al.,
2009). Accordingly, cell volume was found to be greatest in the
M phase and smallest in the G1 phase in CNE-2Z cells and
to increase in parallel to the G1-S transition in fibroblasts (see
Hoffmann et al., 2009) In Ehrlich Lettre ascites carcinoma (ELA)
cells, significant water uptake and cell swelling occur in S phase
(Klausen et al., 2010). The direct effects of changes in cell vol-
ume on the cell cycle control are still not clear, but it seems
that RTKs and mitogen-activated protein kinases (MAPKs) play
important roles. Accordingly, cell swelling induced by hypos-
motic stress in general stimulates extracellular signal regulated
kinase (ERK1/2), a major player in control of cell cycle progres-
sion (see e.g., Meloche and Pouyssegur, 2007; Hoffmann et al.,
2009) and multiple Src family kinases are activated in response
to cell swelling (Cohen, 2005). An interesting example, some-
what in contrast to the general picture given above, is described
in glioma cells, where a marked premitotic cell shrinkage is nec-
essary for the following cell division (Habela and Sontheimer,
2007).
Several types of ion channels have been implicated in the dys-
regulated control of cell cycle progression in cancer (Figure 2).
TRP channels. The resting level of [Ca2+]i varies through the cell
cycle (Schreiber, 2005). Thus, transient changes in [Ca2+]i occur
at the exit from quiescence in early G1, at the G1/S phase tran-
sition and at the exit fromM phase (Munaron, 2002; Munaron
et al., 2004). In some cell types, TRPC1 is proposed to be involved
in Ca2+ influx, RVD and cell cycle progression (Golovina et al.,
2001; Salido et al., 2011; Madsen et al., 2012). A variety of K+
channels have been implicated in the regulation of proliferation
(Takahashi et al., 1993; Pei et al., 2003; Wang, 2004; Voloshyna
et al., 2008) and cell cycle progression (Wang et al., 1998; Felipe
et al., 2006). Accordingly, epithelial carcinomas often show high
K+ channel activity (Patel and Lazdunski, 2004; Wang, 2004;
Felipe et al., 2006). Thus increased TREK-1 channel expression
is associated with abnormal cell proliferation in prostate can-
cer cell lines and TREK-1 may be a novel molecular target in
prostate cancer (Voloshyna et al., 2008). The Kv10.1 (KCNH1)
channel, which is widely studied in cancer, is important for cell
cycle progression and is regulated through the cell cycle (Pardo
et al., 2012). Thus, developing specific blockers for these chan-
nels in the treatment of cancer is a promising field (Felipe et al.,
2006; Li and Xiong, 2011; Pardo et al., 2012). In PDAC, in
addition to Kv10.1 (Gomez-Varela et al., 2007), expression of
IK (KCa3.1) is up-regulated in cancer tissue and some PDAC
cell lines in which it contributes to stimulation of cell prolif-
eration (Jager et al., 2004). Cl− channels are also involved in
control of cell proliferation, and Cl− channel blockers inhibit
cell proliferation (Voets et al., 1995; Pappas and Ritchie, 1998;
Rouzaire-Dubois et al., 2000; Shen et al., 2000; Wondergem et al.,
2001; Chen et al., 2007; Klausen et al., 2010) Several studies have
found that VRAC currents differ in magnitude during the cell
cycle (Shen et al., 2000; Doroshenko et al., 2001; Klausen et al.,
2007, 2010). In nasopharyngeal carcinoma cells, VRAC activity
was found to be central in control of passage through the G1
restriction point (Chen et al., 2007). The Ca2+-activated Cl−
channel TMEM16A (ANO-1) is overexpressed in many carcino-
mas, including human prostate carcinoma (Liu et al., 2012) and
head and neck squamous cell carcinomas, where it induces stim-
ulation of ERK1/2 and contributes to cell proliferation (Duvvuri
et al., 2012). In mammary cancer, where TMEM16A (ANO-1)
is also over-expressed and supports proliferation, it is linked
to EGF receptor and calmodulin-dependent kinase II signaling
(Britschgi et al., 2013). Thus, specific blockers of Cl− channels
are also a potentially interesting field in the treatment of cancer
(Duvvuri et al., 2012; Mazzone et al., 2012). Also several volume-
regulatory transporters, including NHE1 (Putney and Barber,
2003) and NKCC1 (Panet et al., 2000) have been shown to exhibit
cell-cycle dependent regulation and/or roles in regulation of cell
proliferation, although the specific mechanisms are not fully elu-
cidated and for NHE1 likely include effects both on pHi and cell
volume.
In conclusion, ion channels and transporters have been impli-
cated in the control of cell cycle checkpoints in normal as well
as cancer cells, and specific types of ion channels seem to play
an important role in tumor cell proliferation. However, a com-
prehensive mechanistic picture of the functional relation between
ion channels and cell proliferation is yet not available (Becchetti,
2011).
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PROGRAMMED CELL DEATH (PCD)
A hallmark of PCD (or its more restrictive term, apoptosis)
is a marked cell shrinkage (Kerr et al., 1972), which is enti-
tled Apoptotic volume decrease, or AVD (Maeno et al., 2000)
(Figure 2). AVD is an early event required for triggering of full-
blown apoptosis (Maeno et al., 2000; Poulsen et al., 2010), and
there is strong evidence that preventing cell volume regulation
after shrinkage is associated with induction of apoptosis (Lang
and Hoffmann, 2012). AVD results from a loss of KCl via K+
and Cl− channels, and concomitant loss of water (Bortner and
Cidlowski, 1998; Okada and Maeno, 2001; Okada et al., 2001;
Okada, 2004; Lang et al., 2007; Poulsen et al., 2010). Apoptosis
thus depends on K+, Cl− and Ca2+ (to activate Ca2+ acti-
vated K+ and Cl− channels) channels, such as, e.g., various
voltage-dependent K+ channels, two-pore K+ channels, Ca2+
activated K+-channels, VRAC, some Ca2+ -activated Cl− chan-
nels of the ANO family and some Ca2+ permeable TRP channels
(see Lehen’kyi et al., 2011; Lang and Hoffmann, 2012). Enhanced
expression of these ion channels in cancer cells will, as described
above, typically stimulate proliferation and migration, but it will
in general also be expected to be pro-apoptotic. It seems to be a
paradox that cancer cells manage to up-regulate channels mainly
involved in proliferation and migration, while at the same time
avoiding the expected pro-apoptotic effect of these channels. We
favor the interpretation that proliferation /cell cycle progression
is dependent on specific windows of temporal-/spatial-/signal-
specific modulation of Cl− and K+-channel activity, whereas
apoptosis may be the result of a longer-term activation of
Cl− and K+-channels (Figure 2). However, elucidation of this
important question will require complete characterization of the
cell-cycle dependent expression- and activity pattern of the spe-
cific channels involved and mapping of their precise subcellular
localization.
Proapoptotic effects of enhanced K+ channel expression
include: (i) hyperpolarization and associated Ca2+ overload; (ii)
AVD; and (iii) increased proteolytic cleavage of pro-caspase 3
secondary to the decrease in intracellular K+ (Lehen’kyi et al.,
2011). The proapoptotic effect of VRAC expression is predomi-
nantly on AVD (see e.g., Poulsen et al., 2010). The TRP channels
are particularly involved in the control of Ca2+ influx partici-
pating in the PCD process (Lehen’kyi et al., 2011). Collectively,
these findings strongly indicate that ion channel dys-regulation
can underlie cancer cell resistance to apoptosis (see below).
This is also the case for several ion transporters. Thus, dur-
ing AVD, cells lose the capacity for counteracting cell shrink-
age by triggering a regulatory volume increase (RVI) response
(Maeno et al., 2006), which would be normally operating in a
healthy cell. In fact, in HeLa cells undergoing apoptosis, the RVI
mechanism seems to be weakened (Numata et al., 2008). The
transporters involved in RVI thus tend to counteracts apopto-
sis. As the most important transport systems in RVI are NKCC1,
NHE1, the Na+/K+ ATPase, and in some cells also ENaC type
cation channels (Hoffmann et al., 2009), it seems likely that
increased expression or function of these in epithelial cancer
would render tumor cells resistant to apoptosis, and in fact,
this has been demonstrated in several types of cancers (see
below).
ION TRANSPORT AND DRUG RESISTANCE IN CANCER
MULTI DRUG RESISTANCE (MDR)
Chemotherapy resistance—cell-intrinsic or acquired—underlies
the failure of most cancer treatments. Many factors are involved
in resistance of cancer cells, such as decreased drug uptake,
increased drug efflux, detoxification, increased DNA repair, and
dys-regulation of apoptotic signaling (Krishna and Mayer, 2000;
Stavrovskaya, 2000; Lothstein et al., 2001; Giacomini et al., 2010).
One of the most important contributions to drug resistance in
solid tumors such as PDAC is a failure to deliver drugs due to
poor vascularization of the tumor and impermeability exhibited
by dense desmoplasia (see section Chemical/physical properties
of the TME for details). The current strategy is to overcome
both physical barriers with multi-drug therapy approach (e.g.,
Provenzano et al., 2012).
ATP-binding cassette (ABC) drug efflux pumps are widely
studied in the context of chemotherapy resistance (see e.g.,
Litman et al., 2001) and will not be discussed here. As described
above [sections Loss of epithelial polarity—implications for ion
transport and Roles of cell volume regulation in cell proliferation
and programmed cell death (PCD)], ion transporters play major
roles in shaping the TME, which is, in turn, very important for
drug delivery/chemotherapy resistance. The other major contri-
bution of ion transporters in drug resistance in cancer is their role
in the resistance to apoptosis, which is one of the major reasons
for chemotherapy cross-resistance.
RESISTANCE TO APOPTOSIS
Resistance to apoptosis can develop when the AVD is prevented.
This can be mediated by down-regulation of the K+ and/or
Cl− channels responsible for AVD, as well as of Ca2+ chan-
nels involved in Ca2+ influx and hence modulation of Ca2+
sensitive apoptotic steps. Alternatively, resistant cell can develop
an enhanced RVI response, which, as described above, counter-
acts AVD, by up-regulation of NHE1, NKCC1, or hypertonically
induced cation channels (HICCS) (Figure 2). Accordingly, it was
demonstrated that Chinese hamster ovary cells, which do not per-
formRVI because they lack of NHE1, are more prone to apoptosis
compared to cells expressing NHE1 (Rotin and Grinstein, 1989).
Moreover, in HeLa cells HICCS rescue cells from staurosporine-
elicited apoptosis (Numata et al., 2008). These studies underscore
the critical role of volume regulation mechanisms in apop-
totic resistance. Finally, although a detailed account of the roles
of intracellular channels and transporters in PCD resistance is
beyond the scope of this review, it may be noted that the mito-
chondrial voltage-dependent anion channel, VDAC-1, has been
identified as a protein associated with resistance to cisplatin
chemotherapy (Tajeddine et al., 2008) and has, although this
remains controversial, been suggested to be part of the mito-
chondrial permeability transition pore, mPTP (see Javadov et al.,
2011).
THE ROLE OF ION CHANNELS IN CHEMOTHERAPY RESISTANCE
Ion movements are important in the regulation of apopto-
sis, but exactly how they are involved in the development of
chemotherapy resistance is not always clear; in Figure 2 and text
below we summarize some molecular candidates. Decreased K+
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permeability seems to be important cause of cancer cell resistance
to apoptosis (Prevarskaya et al., 2010). For example, in PDAC,
expression of Kv1.3 is down-regulated, presumably due to aber-
rant methylation of the Kv1.3 gene promoter, and it is postulated
that this may render cells resistant to apoptosis (Brevet et al.,
2009). Furthermore, the K+ ionophore amphotericin B coun-
teracts cisplatin resistance in cancer cell lines (Morikage et al.,
1993; Beketic-Oreskovic and Osmak, 1995) by introduction of a
high K+ permeability, and Amphotericin B in conjunction with
the NKCC blocker bumetanide was shown to augment cisplatin-
induced caspase 3 activation (Marklund et al., 2000, 2001, 2004).
The TASK-2 K+ channel blocker clofilium prevents AVD and
abrogates cisplatin-induced caspase 3 activity in a cell line derived
from mammary gland adenocarcinomas, Ehrlich ascites tumour
cells (EATCs) (Poulsen et al., 2010). Targeting BK (KCa1.1) chan-
nels with teraethylammonium or iberiotoxin similarly attenuates
cisplatin-induced apoptosis in spiral ligament fibrocytes of the
cochlea (Liang et al., 2005). Several human cancers are charac-
terized by a reduced expression of the redox-sensitive K+ chan-
nel Kv1.5 (Bonnet et al., 2007) and down-regulation of Kv1.5
channels in human gastric cancer cells enhances resistance to
apoptosis-inducing drugs such as cisplatin (Han et al., 2007). In
PDAC, Kv1.3 is down-regulated (Brevet et al., 2009). In addition,
TASK-3 (Kcnk9) has been shown to have oncogenic potential in
several types of human carcinomas (Pei et al., 2003). Since K+
channels control cell membrane potential and thus Ca2+ influx,
the effect of down-regulating K+ channels on resistance to apop-
tosis can be also mediated by a decreased Ca2+ influx (see also
below).
Decreased Cl− permeability
Induction of apoptosis involves activation of VRAC in several cell
types (d’Anglemont de et al., 2004, 2008; Ise et al., 2005; Poulsen
et al., 2010). Moreover, some studies have shown a decrease
in Cl− permeability in various MDR cell models (Gollapudi
et al., 1992; Lee et al., 2007; Poulsen et al., 2010; Min et al.,
2011). The MDR-EATC and the KCP-4 human epidermoid can-
cer cells, which exhibit acquired resistance to cisplatin, both
have strongly decreased VRAC activity (Lee et al., 2007; Poulsen
et al., 2010). In KCP-4 cells it was further shown that restora-
tion of the channel’s functional expression leads to a decrease
in the cisplatin resistance (Lee et al., 2007). Similar results
were obtained in human lung adenocarcinoma cells (Min et al.,
2011). In wild type EATC, cisplatin treatment induced an AVD
response, whereas MDR-EATC showed almost no AVD response
when treated with cisplatin (Poulsen et al., 2010). This indicates
that impaired activity of VRAC channels contributes to the cis-
platin resistance in MDR-EATC by preventing the necessary AVD
process.
Ca2+ influx
The roles of Ca2+ transport in cancer and chemotherapy resis-
tance have been excellently reviewed elsewhere (Prevarskaya
et al., 2010, 2013; Dubois et al., 2013) and will only be briefly
outlined here. As excessive Ca2+-influx contributes to PCD,
conversely, preventing Ca2+ influx tends to help the cell to
avoid PCD. In agreement with this, apoptosis-resistant prostate
cancer cells have strongly reduced levels of store-operated cal-
cium entry (SOCE) (Vanden Abeele et al., 2002; Vanoverberghe
et al., 2004; Prevarskaya et al., 2013). The Orai protein is an
important component of SOCE, thus down-regulation of Orai
will protect the cancer cells from apoptosis. Accordingly, Orai1
was shown to contribute to the establishment of an apoptosis-
resistant phenotype in prostate cancer cells (Flourakis et al.,
2010).
pH-REGULATORY ION TRANSPORT PROTEINS IN DRUG RESISTANCE IN
CANCER CELLS
A growing body of evidence implicates pH-regulatory ion trans-
porters in drug resistance in cancer. The contributions of these
transporters to resistance occurs at several levels. Firstly, the acidic
extracellular environment in solid tumors, including the cre-
ation of a strongly acidic pericellular subdomain due to rapid
H+ efflux (Stock et al., 2007), will, all things equal, decrease the
uptake by diffusion across the plasma membrane, of chemother-
apeutic drugs which are weak bases, such as doxorubicine and
vinblastine, and can alter the carrier-mediated uptake of drugs
via pH sensitive uptake carriers (Tredan et al., 2007). Once the
drug is inside the cell, the normal-to-alkaline pHi, created in
the tumor cytoplasm through rapid acid extrusion, impacts on
the cell death machinery via multiple pathways (Pedersen, 2006).
Most work in this context has been done on NHE1, inhibition or
knockdown of which has been shown to enhance chemotherapeu-
tically induced cell death in a number of cancer types (Reshkin
et al., 2003; Rebillard et al., 2007; Lauritzen et al., 2010; Jin
et al., 2011). Also proton pump inhibitors have been effectively
used to combat chemotherapy resistance in some cancers (for
a review, see De Milito and Fais, 2005), although the mecha-
nisms are less clear, as theH+ V-ATPases generally predominantly
localize to the endosomal/lysosomal compartments, and at least
in some cancers appear to contribute little to cytosolic pH reg-
ulation (Lauritzen et al., 2010; Hulikova et al., 2013). Finally,
inhibition of monocarboxylate carriers (MCTs) in cancer cells
that strongly dependent on these transporters should also in
principle sensitize cells to chemotherapy, however, little work
has so far been done to address this directly (see Halestrap,
2013).
SUMMARY AND PERSPECTIVES
Epithelial cells are endowed with specific sets of ion channels
and transporters that are organized in a polarized fashion specific
for the function of the given epithelium. The molecular iden-
tities, regulation and roles of these channels and transporters
in the physiology of epithelial transport and cell volume regu-
lation are relatively well understood. Epithelial cells, no doubt
due to their high proliferative rate, but perhaps also due to their
continuously challenged cell volume regulation, walk a thin line
between physiology and pathophysiology. We suggest, specula-
tively, that this may endow them with an inherently increased
risk of undergoing key events contributing to development of
carcinomas. It is interesting to note that in particular epithelia
capable of secretion, such as prostate, mammary glands, colorec-
tum, lung/bronchi, pancreas, stomach, and uterus seem to be
frequent sites of cancer (Siegel et al., 2013). Does dys-regulation
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of existing ion channels/transporters, or changes in the expres-
sion of the channels lead to altered cell volume regulation
and thus increased proliferation, resistance to apoptosis and
chemotherapy? In this review, we have summarized existing evi-
dence for dys-regulation of some of the important ion chan-
nels/transporters, generally from cell culture models. However,
much more knowledge is needed on genuine epithelial can-
cer models as well as on epithelial cancers in vivo. The com-
plex TME contains a number of local auto- and paracrine
agents, and exhibits marked changes in pH, oxygen levels, and
probably ion concentrations, compared to the normal epithe-
lial extracellular environment. Moreover, transformed epithe-
lial cells frequently undergo EMT, the basal membrane is
degraded, and the epithelial cells come into contact with cell
types they would not normally encounter. Future studies should
map and functionally characterize the complete ion “trans-
portomes” for the different cell types within the tumor, in order
to uncover novel multi-therapeutic approaches to carcinoma
chemotherapy.
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